On March 25, Renfu Pharmaceutical announced that recently, Hubei Gedian Renfu Pharmaceutical Co.
, a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.
Mifepristone tablets are currently widely used pregnancy termination drugs.
This approval adds a scope of applicable population for termination of pregnancy within 8-16 weeks (50-112 days).
Jiulong Renfu submitted an application for consistency evaluation to the State Food and Drug Administration in 2019 and was accepted, with a cumulative R&D investment of approximately RMB 16 million.
According to the website of the State Drug Administration, a total of 7 domestic companies hold production approvals for mifepristone tablets.
It is specially reminded that the board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint responsibility for the authenticity, accuracy and completeness of the contents.
According to the statistics of Meinnet.
com, the sales of the full dosage form of mifepristone in my country's city, county and township three terminal public hospitals in 2019 is about 240 million yuan.
The main manufacturers include Hubei Gedian Renfu Pharmaceutical Co.
Company (including Jiulong Renfu), China Resources Zizhu Pharmaceutical Co.
, Zhejiang Xianju Pharmaceutical Co.